Optio attends the 11th Annual CHDI HD Therapeutics Conference February 22-25, 2016

February 2016 – Optio met with global thought leaders in Huntington’s disease, reinforcing Optio’s 10+ years of thought leader relationships and expertise in pharmaceutical commercial planning and market research in Huntington’s disease and other CNS markets. Optio is a leader in pharmaceutical market research and commercial services for movement disorders such as Parkinson’s disease, Huntington’s disease, and Multiple Sclerosis. Optio has deep experience with other neurological disorders such as Alzheimer’s and has conducted many orphan drug or ultra-orphan drug market consulting and market research projects.

Leave a Reply